Search Results - "Redig, Amanda J."

Basket trials and the evolution of clinical trial design in an era of genomic medicine by Redig, Amanda J, Jänne, Pasi A

Get full text

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints by Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

“…Despite compelling antitumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung…”
Get full text

Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression by Shields, Mario A, Dangi-Garimella, Surabhi, Redig, Amanda J, Munshi, Hidayatullah G

“…PDAC (pancreatic ductal adenocarcinoma) is among the most deadly of human malignances. A hallmark of the disease is a pronounced collagen-rich fibrotic…”
Get more information

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors by Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M, Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E, Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J, Bahcall, Magda, Oxnard, Geoffrey R, Eck, Michael J, Jänne, Pasi A

“…Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these…”
Get full text

Pathogenesis and clinical implications of HIV-related anemia in 2013 by Redig, Amanda J, Berliner, Nancy

“…Anemia is a common feature of HIV-related disease and has been uniformly demonstrated to be an independent predictor of morbidity and mortality. Although…”
Get full text

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer by Redig, Amanda J, Capelletti, Marzia, Dahlberg, Suzanne E, Sholl, Lynette M, Mach, Stacy, Fontes, Caitlin, Shi, Yunling, Chalasani, Poornima, Jänne, Pasi A

“…NF1 is a tumor suppressor that negatively regulates Ras signaling. NF1 mutations occur in lung cancer, but their clinical significance is unknown. We evaluated…”
Get full text

Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer by Bahcall, Magda, Awad, Mark M, Sholl, Lynette M, Wilson, Frederick H, Xu, Man, Wang, Stephen, Palakurthi, Sangeetha, Choi, Jihyun, Ivanova, Elena V, Leonardi, Giulia C, Ulrich, Bryan C, Paweletz, Cloud P, Kirschmeier, Paul T, Watanabe, Masayuki, Baba, Hideo, Nishino, Mizuki, Nagy, Rebecca J, Lanman, Richard B, Capelletti, Marzia, Chambers, Emily S, Redig, Amanda J, VanderLaan, Paul A, Costa, Daniel B, Imamura, Yu, Jänne, Pasi A

“…MET inhibitors can be effective therapies in patients with exon 14 ( ex14) mutant non-small cell lung cancer (NSCLC). However, long-term efficacy is limited by…”
Get full text

Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 by Zhang, Haikuo, Fillmore Brainson, Christine, Koyama, Shohei, Redig, Amanda J., Chen, Ting, Li, Shuai, Gupta, Manav, Garcia-de-Alba, Carolina, Paschini, Margherita, Herter-Sprie, Grit S., Lu, Gang, Zhang, Xin, Marsh, Bryan P., Tuminello, Stephanie J., Xu, Chunxiao, Chen, Zhao, Wang, Xiaoen, Akbay, Esra A., Zheng, Mei, Palakurthi, Sangeetha, Sholl, Lynette M., Rustgi, Anil K., Kwiatkowski, David J., Diehl, J Alan, Bass, Adam J., Sharpless, Norman E., Dranoff, Glenn, Hammerman, Peter S., Ji, Hongbin, Bardeesy, Nabeel, Saur, Dieter, Watanabe, Hideo, Kim, Carla F., Wong, Kwok-Kin

“…Adenosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity. Here, we demonstrate lineage switching of KRAS+ lung…”
Get full text

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer by Krall, Elsa B, Wang, Belinda, Munoz, Diana M, Ilic, Nina, Raghavan, Srivatsan, Niederst, Matthew J, Yu, Kristine, Ruddy, David A, Aguirre, Andrew J, Kim, Jong Wook, Redig, Amanda J, Gainor, Justin F, Williams, Juliet A, Asara, John M, Doench, John G, Janne, Pasi A, Shaw, Alice T, McDonald Iii, Robert E, Engelman, Jeffrey A, Stegmeier, Frank, Schlabach, Michael R, Hahn, William C

“…Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other…”
Get full text

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors by ALTMAN, Jessica K, SASSANO, Antonella, KAUR, Surinder, GLASER, Heather, KROCZYNSKA, Barbara, REDIG, Amanda J, RUSSO, Suzanne, BARR, Sharon, PLATANIAS, Leonidas C

“…To determine whether mTORC2 and rapamycin-insensitive (RI)-mTORC1 complexes are present in acute myeloid leukemia (AML) cells and to examine the effects of…”
Get full text

Care of the Cancer Survivor: Metabolic Syndrome after Hormone-Modifying Therapy by Redig, Amanda J., PhD, Munshi, Hidayatullah G., MD

“…Abstract Emerging evidence implicates metabolic syndrome as a long-term cancer risk factor but also suggests that certain cancer therapies might increase…”
Get full text

Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses by Joshi, Sonali, Kaur, Surinder, Redig, Amanda J, Goldsborough, Katy, David, Kevin, Ueda, Takeshi, Watanabe-Fukunaga, Rie, Baker, Darren P, Fish, Eleanor N, Fukunaga, Rikiro, Platanias, Leonidas C

“…We provide evidence for the existence of an IFN-regulated cellular pathway involving the mitogen-activated protein kinase (MAPK)-integrating kinase (Mnk) 1…”
Get full text

Suppressive effects of statins on acute promyelocytic leukemia cells by SASSANO, Antonella, KATSOULIDIS, Efstratios, ANTICO, Giovanni, ALTMAN, Jessica K, REDIG, Amanda J, MINUCCI, Saverio, TALLMAN, Martin S, PLATANIAS, Leonidas C

“…The family of statins includes pharmacologic inhibitors of the 3-hydroxy-3-methylglutaryl-CoA reductase that are potent regulators of cholesterol biosynthesis…”
Get full text

Erratum: Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2 by Zhang, Haikuo, Brainson, Christine Fillmore, Koyama, Shohei, Redig, Amanda J., Chen, Ting, Li, Shuai, Gupta, Manav, Garcia-de-Alba, Carolina, Paschini, Margherita, Herter-Sprie, Grit S., Lu, Gang, Zhang, Xin, Marsh, Bryan P, Tuminello, Stephanie J., Xu, Chunxiao, Chen, Zhao, Wang, Xiaoen, Akbay, Esra A., Zheng, Mei, Palakurthi, Sangeetha, Sholl, Lynette M., Rustgi, Anil K., Kwiatkowski, David J., Alan Diehl, J., Bass, Adam J., Sharpless, Norman E., Dranoff, Glenn, Hammerman, Peter S., Ji, Hongbin, Bardeesy, Nabeel, Saur, Dieter, Watanabe, Hideo, Kim, Carla F., Wong, Kwok-Kin

“…Nature Communications 8: Article number: 14922 (2017); Published 7 April 2017; Updated 9 June 2017 The affiliation details for Hideo Watanabe are incorrect in…”
Get full text

Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study by Cagney, Daniel N, Martin, Allison M, Catalano, Paul J, Redig, Amanda J, Lin, Nancy U, Lee, Eudocia Q, Wen, Patrick Y, Dunn, Ian F, Bi, Wenya Linda, Weiss, Stephanie E, Haas-Kogan, Daphne A, Alexander, Brian M, Aizer, Ayal A

“…Brain metastases are associated with significant morbidity and mortality. Population-level data describing the incidence and prognosis of patients with brain…”
Get full text

Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses by Altman, Jessica K., Yoon, Patrick, Katsoulidis, Efstratios, Kroczynska, Barbara, Sassano, Antonella, Redig, Amanda J., Glaser, Heather, Jordan, Alison, Tallman, Martin S., Hay, Nissim, Platanias, Leonidas C.

“…Arsenic trioxide (As2O3) is a potent inducer of apoptosis of leukemic cells in vitro and in vivo, but the mechanisms that mediate such effects are not well…”
Get full text

The protein kinase C (PKC) family of proteins in cytokine signaling in hematopoiesis by Redig, Amanda J, Platanias, Leonidas C

“…The members of the protein kinase C (PKC) family of proteins play important roles in signaling for various growth factors, cytokines, and hormones. Extensive…”
Get more information

Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib by Oxnard, Geoffrey R, Hu, Yuebi, Mileham, Kathryn F, Husain, Hatim, Costa, Daniel B, Tracy, Philip, Feeney, Nora, Sholl, Lynette M, Dahlberg, Suzanne E, Redig, Amanda J, Kwiatkowski, David J, Rabin, Michael S, Paweletz, Cloud P, Thress, Kenneth S, Jänne, Pasi A

“…Osimertinib mesylate is used globally to treat EGFR-mutant non-small cell lung cancer (NSCLC) with tyrosine kinase inhibitor resistance mediated by the EGFR…”
Get more information

Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2 by Dolniak, Blazej, Katsoulidis, Efstratios, Carayol, Nathalie, Altman, Jessica K., Redig, Amanda J., Tallman, Martin S., Ueda, Takeshi, Watanabe-Fukunaga, Rie, Fukunaga, Rikiro, Platanias, Leonidas C.

“…Arsenic trioxide (As2O3) is a potent inducer of apoptosis of malignant cells in vitro and in vivo, but the precise mechanisms by which it mediates such effects…”
Get full text

Targeting BET bromodomain proteins in solid tumors by Sahai, Vaibhav, Redig, Amanda J, Collier, Katharine A, Eckerdt, Frank D, Munshi, Hidayatullah G

“…There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal) proteins because of the association between this family of proteins…”
Get full text